P21、p53蛋白和增殖细胞核抗原在膀胱癌中的表达及意义

Expression of P21, p53 and proliferating cell nuclear antigen in human bladder cancer.

目的研究同一膀胱癌中癌基因蛋白产物和抗癌基因蛋白产物的表达。方法应用免疫组织化学ＡＢＣ方法检测５例正常膀胱组织和５８例膀胱癌组织中增殖细胞核抗原（ＰＣＮＡ），Ｐ２１和ｐ５３蛋白的表达水平。结果５例正常膀胱组织中未发现Ｐ２１，ｐ５３和ＰＣＮＡ的表达，５８例膀胱癌组织中Ｐ２１，ｐ５３和ＰＣＮＡ阳性检出率分别为６２．１％、５５．２％和５８．６％。表达阳性的ＰＣＮＡ和ｐ５３均定位于肿瘤细胞核内，Ｐ２１蛋白定位于细胞膜上。Ｐ２１，ｐ５３和ＰＣＮＡ阳性表达率与膀胱癌的病理分级，临床分期和患者术后生存率关系密切。结论检测ｐ２１，ｐ５３和ＰＣＮＡ有助于评估膀胱癌的预后。

Objective To study the expression of cancer gene product and anti cancer gene product in the same bladder cancer. Methods Immunohistochemical staining was used to determine the expression of P21, p53 and proliferating cell nuclear antigen (PCNA) in 5 normal bladder tissues and 58 bladder cancers. Results No P21, p53 and PCNA were expressed in the 5 normal bladder tissue samples. The positive incidence of P21, p53 and PCAN expression in the bladder cancers were 62.1%, 55.2% and 58.6% respectively. p53 and PCNA were located in cell nuclei and P21 located on the cell membrane in bladder cancer. The expression of P21, p53 and PCNA correlated to the stage, clinical grade and patient survival rates of this tumor. Conclusion These results suggest that P21, p53 and PCNA immunolabelling may be used to determine the prognosis of bladder cancer patients.